Rebus Holdings, Inc. (RBSH)
OTCMKTS: RBSH · Delayed Price · USD
0.0001
0.00 (0.00%)
Apr 11, 2024, 2:46 PM EDT - Market open
Company Description
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer.
Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally.
Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
Rebus Holdings, Inc.
Country | United States |
Founded | 2003 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 1 |
CEO | Raul Silvestre Esq. |
Contact Details
Address: 2629 Townsgate Rd, Suite 215 Westlake Village, California 91361 United States | |
Phone | (210) 479-8112 |
Website | rebus-corp.com |
Stock Details
Ticker Symbol | RBSH |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001421204 |
CUSIP Number | 75619J103 |
ISIN Number | US75619J1034 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Raul Silvestre Esq. | Chief Executive Officer, Chief Financial Officer, President, Principal Accounting Officer and Director |
Dr. John T. Isaacs Ph.D. | Co-Founder, Chairman of Scientific Advisory Board and Chief Scientific Advisor |
Dr. Samuel R. Denmeade M.D. | Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Aug 21, 2023 | 10-Q | Quarterly Report |
Aug 14, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
May 15, 2023 | 10-Q | Quarterly Report |
Mar 31, 2023 | 10-K | Annual Report |
Jan 10, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 21, 2022 | 10-Q | Quarterly Report |
Nov 16, 2022 | 8-K | Current Report |
Nov 14, 2022 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
Oct 13, 2022 | 8-K | Current Report |
Aug 12, 2022 | 10-Q | Quarterly Report |